Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular death. As phospholipids have also been linked with CVD risk, we investigated whether the combination of ceramides with phosphatidylcholines (PCs) would be synergistic in the prediction of CVD events in patients with atherosclerotic coronary heart disease in three independent cohort studies.

Related collections

Most cited references 10

Record: found
Abstract: found
Article: not found

Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea).

Dong D Wang, Estefanía Toledo, Adela Hruby … (2017)

Although in vitro studies and investigations in animal models and small clinical populations have suggested that ceramides may represent an intermediate link between overnutrition and certain pathological mechanisms underlying cardiovascular disease (CVD), no prospective studies have investigated the association between plasma ceramides and risk of CVD.

0 comments Cited 121 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.

Johannes Dorresteijn, Martijn Gondrie, Frank L. J. Visseren … (2013)

To enable risk stratification of patients with various types of arterial disease by the development and validation of models for prediction of recurrent vascular event risk based on vascular risk factors, imaging or both. Prospective cohort study. University Medical Centre. 5788 patients referred with various clinical manifestations of arterial disease between January 1996 and February 2010. 788 recurrent vascular events (ie, myocardial infarction, stroke or vascular death) that were observed during 4.7 (IQR 2.3 to 7.7) years' follow-up. Three Cox proportional hazards models for prediction of 10-year recurrent vascular event risk were developed based on age and sex in addition to clinical parameters (model A), carotid ultrasound findings (model B) or both (model C). Clinical parameters were medical history, current smoking, systolic blood pressure and laboratory biomarkers. In a separate part of the dataset, the concordance statistic of model A was 0.68 (95% CI 0.64 to 0.71), compared to 0.64 (0.61 to 0.68) for model B and 0.68 (0.65 to 0.72) for model C. Goodness-of-fit and calibration of model A were adequate, also in separate subgroups of patients having coronary, cerebrovascular, peripheral artery or aneurysmal disease. Model A predicted 30% risk in 23%. Patients at high risk for recurrent vascular events can be identified based on readily available clinical characteristics.

0 comments Cited 93 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention PopulationClinical Perspective

Lotte Kaasenbrood, S Boekholdt, Yolanda van der Graaf … (2016)

Among patients with clinically manifest vascular disease, the risk of recurrent vascular events is likely to vary. We assessed the distribution of estimated 10-year risk of recurrent vascular events in a secondary prevention population. We also estimated the potential risk reduction and residual risk that can be achieved if patients reach guideline-recommended risk factor targets.

0 comments Cited 82 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: European Heart Journal

Publisher: Oxford University Press (OUP)

ISSN (Print): 0195-668X

ISSN (Electronic): 1522-9645

Publication date Created: June 18 2019

Publication date (Electronic): June 18 2019

Affiliations

[1 ]Zora Biosciences Oy, Tietotie 2C, 02150 Espoo, Finland

[2 ]Metabolomics Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne VIC 3004, Australia

[3 ]Department of Diabetes, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, 99 Commercial Road, Melbourne VIC 3004, Australia

[4 ]Department of Heart Disease, Haukeland University Hospital, Jonas Lies veg 65, 5021 Bergen, Norway

[5 ]Department of Global Public Health and Primary Care, University of Bergen, Kalfarveien 31, 5020 Bergen, Norway

[6 ]Department of Clinical Science, University of Bergen, Jonas Lies veg 87, 5021 Bergen, Norway

[7 ]Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, D-69120 Heidelberg, Germany

[8 ]Network Ageing Research, University of Heidelberg, Bergheimer Straße 20, D-69115 Heidelberg, Germany

[9 ]School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne VIC 3004, Australia

[10 ]Department of Chemical Pathology, Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown NSW 2050, Sydney, Australia

[11 ]The NHMRC Clinical Trials Centre, University of Sydney, 92-94 Parramatta Rd, Camperdown NSW 2050, Sydney, Australia

[12 ]Heart Centre, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne VIC 3004, Australia

[13 ]Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, D-80636 Munich, Germany

[14 ]DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Lazarettstr. 36, D-80636 Munich, Germany

[15 ]Institute of Epidemiology and Medical Biometry, Helmholtzstr. 22, D-89081 Ulm University, Ulm, Germany

[16 ]Finnish Cardiovascular Research Center, University of Tampere, Arvo Ylpön katu 34, 33520 Tampere, Finland

[17 ]Finnish Clinical Biobank Tampere, Tampere University Hospital, Biokatu 12, 33520 Tampere, Finland

Article

DOI: 10.1093/eurheartj/ehz387

PubMed ID: 31209498

SO-VID: c720dbf2-e11d-4a05-96c9-914da2255267

License:

http://creativecommons.org/licenses/by-nc/4.0/

History

Data availability:

Comments

Comment on this article

scite_

Cited by 83

See all cited by

Most referenced authors 709

See all reference authors

- Version 1

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients

Read this article at

Abstract

Related collections

Recursive Rule based Visual Categorization

Most cited references 10

Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea).

Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention PopulationClinical Perspective

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 1,719

Cited by 83

Most referenced authors 709